Why Biopharma Companies Are Partnering with CDMOs for Large...

added blog Health

2026-06-16 07:00:04 -

Why Biopharma Companies Are Partnering with CDMOs for Large Molecule Manufacturing

The U.S. large molecule drug substance CDMO market reached a valuation of USD 12.34 billion in 2024 and is expected to grow at a CAGR of 7.5% between 2025 and 2034, reflecting strong demand across multiple product, application, and end-use segments. The market’s expansion is inseparably linked to the evolving structure of biologics manufacturing, marked by rapid innovation cycles, rising...

0 Comments 0 Shares 146 Views 0 Reviews